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e appreciate the comments from Drs. Kassimatis and Konstanti-
opoulos concerning our review (1). The pre-clinical evidence
uggesting that statins may cause renal fibrosis, mediated by
ransforming growth factor-beta signaling, is interesting but does
ot negate other pre-clinical studies suggesting reno-protection.
hen examining the randomized controlled clinical trial evidence
the gold standard), the totality of evidence does not indicate a
tatin-induced deleterious effect (2,3). A detailed discussion of
re-clinical trials was beyond the scope of our review, and it was
ur goal to provide some balance and perspective to the inordinate
mount of attention focused on statin-induced proteinuria after
he introduction of rosuvastatin.
We acknowledge that some pre-clinical trials indicate statins
ay have an immunomodulatory role; however, prospective ran-
omized controlled trials to date do not demonstrate a clinically
ignificant effect. In the 4D (Die Deutsche Diabetes Dialyse
tudie) trial with diabetic hemodialysis patients, there was no
ignificant difference in fatal infections in the atorvastatin arm
n 60) compared with that in the placebo arm (n 68) (4). The
LERT (Assessment of Lescol in Renal Transplantation Trial)
tudy was comprised of renal transplant patients with varying
egrees of renal insufficiency who were immunocompromised due
o cyclosporine and other immunosuppressant drugs, yet fluva-
tatin and placebo infection rates were not significantly different
fluvastatin [n  25], placebo [n  26]) (5).
Finally, we do not advocate the use of statins as renoprotective
gents; however, we do not believe there is sufficient evidence to
iscourage the use of these agents in chronic kidney disease (CKD)
atients who are at high risk of developing coronary heart disease
1). In fact, the National Kidney Foundation clinical practice
uidelines state that CKD patients should be placed in the “highest
isk” category for cardiovascular disease (6). The real question is
ot whether statins are a double-edged sword; rather, are they an
nderutilized weapon in the battle to prevent coronary heart
isease in CKD patients?
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he DELFT (Drug Eluting
tent for LeFT main) Registry:
he Unknowns
eliga et al. (1) are to be congratulated on their report from the
ELFT (Drug Eluting stent for LeFT main) registry of “long-
erm” outcomes after drug-eluting stents for unprotected left main
oronary artery disease.
They raise, however, 3 important issues that need further
larification.
First, rather than presenting total mortality, which is obligatory
or reporting of surgical outcomes, they present the incidence of
ardiac death, according to the Academic Research Consortium
efinition. This sets a dangerous precedent, as cardiac mortality is
less objective outcome measure than total mortality, and a better
ompromise would be to present both; presentation of total
ortality should, however, remain mandatory.
Second, during the period of the study, 680 patients underwent
oronary artery bypass grafting in the 7 participating centers.
here are no data to inform whether coronary artery bypass
rafting patients differed systematically from those undergoing
tenting in terms of complexity of left main disease, severity of
oncomitant multivessel coronary artery disease, existence of co-
orbid conditions, or, indeed, how the decision was made as to
hich intervention patients would receive.
Third, there is no explicit statement as to whether all interven-
ions were decided by a multidisciplinary team including a surgeon.
he increasing tendency to report interventional treatments being
ased on “patient or physician preference” is both inadequate and
nappropriate because it reduces the likelihood that patients will
eceive impartial information and, as a consequence, will not
nsure that there is, therefore, real patient choice and genuine
nformed consent. Unless a patient is clearly unfit or unwilling to
ursue a surgical option, discussion of all interventions by a
ultidisciplinary team should be a minimum standard of care
2–4).
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